Literature DB >> 2885402

Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.

L H Elliott, W H Brooks, T L Roszman.   

Abstract

The responsiveness of T cells and their subsets (T-helper cells and T-suppressor cells) obtained from patients with malignant gliomas was evaluated in an effort to further define the mechanism of their impaired host immunocompetence. This study demonstrates that peripheral blood lymphocytes obtained from these patients have impaired responsiveness to a variety of mitogens including phytohemagglutinin, concanavalin A, pokeweed mitogen, and anti-T3 monoclonal antibody. The impaired lymphocyte responsiveness does not result from the inability of these cells to express receptors for a specific mitogen or antibody. The mitogenic responsiveness of purified T cells is markedly reduced when compared to values obtained from control subjects. Therefore, the decreased T cell reactivity of patients with malignant gliomas does not result simply from a diminution in the absolute number of potentially responding lymphocytes. The mitogen reactivity of the T cell subsets, CD4+ helper cells, and CD8+ cytotoxic/suppressor cells was also investigated. These results demonstrate that the responsiveness of the CD4+ T-helper cell subset obtained from these patients is consistently diminished as compared to control values. In contrast, the reactivity of the CD8+ T cell subset was not nearly as dramatically impaired. Thus, these results indicate that the proliferative defect observed in T cells obtained from patients is located predominantly in the T-helper cell subset. Functional deficiencies in this important subpopulation of T lymphocytes may explain, in part, the presence of depressed immune responsiveness in patients with malignant glial tumors.

Entities:  

Mesh:

Year:  1987        PMID: 2885402     DOI: 10.3171/jns.1987.67.2.0231

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 3.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 4.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07

Review 5.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

Review 6.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 7.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

8.  Identification of HLA a*0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SSP and DNA sequencing.

Authors:  An-Hua Wu; Walter A Hall; Walter C Low
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

9.  Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation and interleukin-2 secretion by physiologic combinations of dexamethasone and prostaglandin E2.

Authors:  L Elliott; W Brooks; T Roszman
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

10.  Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model.

Authors:  M Wiranowska; A A Gonzalvo; S Saporta; O R Gonzalez; L D Prockop
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.